Celularity, Inc. is a clinical-stage biotechnology company headquartered in Palm Beach Gardens, Florida. The company harnesses postpartum placental and umbilical cord blood tissues to derive allogeneic cell therapies with a focus on immuno-oncology and regenerative medicine. It maintains one of the world’s largest placenta-derived cell banks, supporting the development of targeted therapies that utilize natural killer (NK) cells, placenta-derived myeloid cells, trophoblasts and exosomes.
Celularity’s lead clinical candidate, CYNK-001, comprises allogeneic natural killer cells being evaluated for the treatment of hematologic malignancies and select solid tumors. In addition to its oncology pipeline, the company is exploring regenerative applications, including placental mesenchymal-like cells and exosome-based products to address inflammatory disorders and promote tissue repair. Its end-to-end capabilities span tissue procurement, process development and GMP manufacturing, enabling scalable production of multiple cell therapy formats.
Founded in 2017 by a team of biotech veterans, Celularity’s leadership includes co-founder and Executive Chairman Dr. Robert Hariri, an immunologist and entrepreneur with decades of experience in stem cell biology. The company operates research and development facilities in Florida, supported by collaborations with academic institutions and pharmaceutical partners. Celularity is advancing its product candidates through regulatory milestones, aiming for approvals in key markets across North America, Europe and Asia.
Listed on the Nasdaq under the ticker CELUW, Celularity leverages strategic collaborations and in‐house research to enhance its pipeline and address unmet medical needs worldwide. The company’s integrated supply chain model, from tissue sourcing to GMP production, supports efficient clinical and commercial scale operations. With multiple product candidates advancing through the clinic, Celularity aims to deliver innovative cell therapies that harness the unique immunological and regenerative properties of placental-derived cells.
AI Generated. May Contain Errors.
MarketBeat All Access